홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.3
  1. 홈
  2. /화합물

비마토프로스트

Bimatoprost

HCID 5311027
새 반응
인쇄
기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
155206-00-1
표준 SMILES
CCNC(=O)CCC/C=C\C[C@@H]1[C@@H](/C=C/[C@@H](O)CCc2ccccc2)[C@H](O)C[C@@H]1O
InChIKey
AQOKCDNYWBIDND-FTOWTWDKSA-N
분자식
C25H37NO4
평균 분자량
415.6 g/mol
단동위원소 질량
415.27225866

개요

Bimatoprost is a monocarboxylic acid amide. It has a role as an antihypertensive agent and an antiglaucoma drug.

이름 및 식별자

우선 이름
Bimatoprost
IUPAC
(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamide
현지명
비마토프로스트
영어명
Bimatoprost
분자식
C25H37NO4
분자량
415.57

이름 및 동의어

Bimatoprost155206-00-1LumiganLatisseAGN 192024ProstamideAGN-192024bimatoprostum(Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxy-5-phenylpent-1-enyl]cyclopentyl]-N-ethylhept-5-enamideDURYSTAQXS94885MZ(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3S)-3-hydroxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-5-heptenamide
이름 더 보기
비마토프로스트Bimabimatoprost powderN-ETHYL-9ALPHA,11ALPHA,15S-TRIHYDROXY-17-PHENYL-18,19,20-TRINOR-PROSTA-5Z, 13E-DIEN-1-AMIDEbimatoprosBimatoprost (W.S)BiMatoprost HOUSE STANDARD17-phenyl-tri-norprostaglandin f2α-ethyl amide17-PHENYL TRINOR PROSTAGLANDIN F2ALPHA ETHYL AMIDE
CHEBI:51230DTXSID30895042GANFORT COMPONENT BIMATOPROSTAGN1920245-Heptenamide, 7-(3,5-dihydroxy-2-(3-hydrdoxy-5-phenyl-1-pentenyl)cyclopentyl)-N-ethyl-, (1R-(1alpha(Z),2beta(1E,3S*),3alpha,5alpha))-(5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl]-N-ethylhept-5-enamide(5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]cyclopentyl}-N-ethylhept-5-enamide192024, AGN

물성

구조 계산 물성

XLogP
2.8
극성 표면적
89.8 Ų
수소 결합 공여자 수
4
수소 결합 수용자 수
4
회전 가능 결합 수
12
무거운 원자 수
30
형식 전하
0
복잡도
541

실험 및 물리화학적 성질

DrugsPharmaceuticals -> Listed in ZINC15
LogP3.2
Solubility · 2건

soluble in water

1.87e-02 g/L

Human Drugs · 4건

Breast Feeding; Lactation; Milk, Human; Antiglaucoma Agents; Prostaglandins

FDA approved drugs -> Active ingredient

EMA approved medicines: Human medicine

FDA approved drugs -> Active ingredient

Melting Point63-67
Physical DescriptionSolid
Dissociation Constants14.3, - 0.23

물리화학적 성질

녹는점
66 · 66-68°C
끓는 점
629.8 · 629.8±55.0 °C(Predicted)
밀도
1.145 · 1.145±0.06 g/cm3(Predicted)
저장 조건
-20 °C · -20°C
용해도
클로로포름(약간 용해됨), 디클로로메탄(약간 용해됨), 메탄올(약간 용해됨)

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Danger

H302 (23.8%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P264+P265, P270, P280, P301+P317, P302+P352, P305+P351+P338, P317, P318, P321, P330, P337+P317, P362+P364, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 21 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (23.8%)

독성 정보

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

wgk
3
Hazard Classifications
Acute Tox. 4 OralRepr. 1B
스토리지 클래스
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects

화학 및 산업

약리 정보

ATC Code · 3건

S01EE03

S - Sensory organs

QS - Sensory organs

Protein BindingBimatoprost is about 88%-90% bound to plasma proteins.
Pharmacodynamics · 1건

High intraocular pressure is a major risk factor for glaucoma-related visual field loss. A linear relationship exists between intraocular pressure and the risk of damaging the optic nerve, which can lead to considerable visual impairment. Therefore, conditions such as ocular hypertension and glaucoma can cause dangerous elevations of intraocular pressure. Bimatoprost rapidly decreases intraocular pressure and reduces the risk for visual field loss from ocular hypertension due to various causes. Other effects of this drug may include gradual changes in eyelid pigmentation, changes in iris pigmentation, changes in eyelash pigmentation, growth and thickness. Patients should be informed of these possible effects, especially if this drug is only administered to one eye, which may noticeably change in appearance with bimatoprost treatment.

Mechanism of Action · 1건

Bimatoprost imitates the effects of prostamides, specifically prostaglandin F2α. Bimatoprost mildly stimulates aqueous humor outflow, relieving elevated intraocular pressure and decreasing the risk of optic nerve damage. It is thought that bimatoprost reduces intraocular pressure (IOP) in humans by causing an increase in outflow of the aqueous humor via the trabecular meshwork and uveoscleral pathways. It achieves the above effects by decreasing tonographic resistance to aqueous humor outflow. Bimatoprost does not affect aqueous humor production.

Biological Half-LifeThe elimination half-life of bimatoprost is approximately 45 minutes.
Metabolism/Metabolites · 1건

Bimatoprost is hydrolyzed to its active form, bimatoprost acid, in the eye. Bimatoprost undergoes oxidation, N-deethylation, and glucuronidation after it is systemically absorbed, and this leads to the production of various metabolites. In vitro studies show that CYP3A4 is an enzyme that participates in the metabolism of bimatoprost. Despite this, many enzymes and pathways metabolize bimatoprost, therefore, no significant drug-drug interactions are likely to occur. Glucuronidated metabolites comprise most of the excreted drug product in the blood, urine, and feces in rats.

관련 반응

9건
반응 기록 만들기
HRID 62567 반응식
HRID 62567반응물로
HRID 422890 반응식
HRID 422890반응물로
HRID 517405 반응식
HRID 517405생성물로
HRID 551520 반응식
HRID 551520반응물로
HRID 591123 반응식
HRID 591123반응물로
HRID 593414 반응식
HRID 593414생성물로
HRID 1621277 반응식
HRID 1621277생성물로
HRID 1621278 반응식
HRID 1621278생성물로
이전1 / 2 페이지

화합물 노트

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트

데이터베이스 식별자

CAS
155206-00-1
PubChem CID
5311027
DTXSID
DTXSID30895042
ChEMBL
CHEMBL1200963
ChEBI
CHEBI:51230
UNII
QXS94885MZ
EC Number
642-890-9
Nikkaji
J1.596.089B
물리적 상태
고체
산도 계수 (pKa)
14.25 · 14.25±0.20(Predicted)
색상
흰색에서 황백색까지
BCS Class
3 · 3
안정성
감광성
화장품 원료 기능
속눈썹 컨디셔닝
InChIKey
AQOKCDNYWBIDND-FTOWTWDKSA-N
SMILES
C(NCC)(=O)CCC/C=C\C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1/C=C/[C@@H](O)CCC1=CC=CC=C1

화학적 성질

Crystalline Solid

FDA Pharmacological Classification · 6건

QXS94885MZ

BIMATOPROST

Established Pharmacologic Class [EPC] - Prostaglandin Analog

Chemical Structure [CS] - Prostaglandins

Bimatoprost is a Prostaglandin Analog.

BIMATOPROST

MeSH Pharmacological Classification · 1건

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Absorption, Distribution and Excretion · 4건

This drug is absorbed systemically when administered to the eye. A study was performed on 15 healthy volunteers and bimatoprost ophthalmic solution 0.03% was administered once daily for 14 days. The mean Cmax was approximately 0.08 ng/mL and AUC0-24hr was approximately 0.09 on days 7 and 14 of the study. By 10 minutes, peak blood concentration was achieved. Bimatoprost was not detectable at 1.5 hours after administration in most subjects. The maximum blood concentration in a study of 6 healthy volunteers was determined to be 12.2 ng/mL. Steady state was reached in the first week of dosing. One drug label mentions that onset of decreased intraocular pressure occurs approximately 4 hours after the first administration and the peak effect occurs in the range of 8-12 hours. Bimatoprost effects may last up to 24 hours.

One pharmacokinetic study of bimatoprost in 6 healthy volunteers determined that 67% of the administered dose was found to be excreted in the urine while 25% of the dose was recovered in the feces.

The volume of distribution at steady state is 0.67 L/kg.. It penetrates the human cornea and sclera.

The clearance was measured to be 1.5 L/hr/kg in healthy subjects receiving IV administration of bimatoprost dosed at 3.12 ug/kg.

Cellular LocationsCytoplasm
응용 분야 · 3건

개요Bimatoprost was first introduced in the US and Brazil as Lumigan, an ophthalmic solution (0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, a proven risk of glaucomatous visual field loss. Bitamoprost is a new agent belonging to the PGF2α analog class of prostamides launched in this indication after latanoprost, the most efficaceous topical medication currently available. This synthetic fatty acid amide can be prepared by esterification of 17- phenyl-18,19,20-trinorprostaglandin F2α followed by ethylamidation. Bimatoprost, as related prostamides, is devoid of typical activities associated with PGF2,, analogs; it exhibits a unique pharmacological profile in contracting the feline iris sphincter with an EC50 of 34 nM without interacting with any known prostanoid receptors. Thus it mimics the action of endogenous prostamides on specific receptors that lower IOP by increasing aqueous humor outflow through both pressure-insensitive and pressure-sensitive pathways without reducing humor formation. In a 3-month controlled clinical trial of efficacy and safety in patients with elevated IOP, bimatoprost demonstrated lower mean intraocular pressures at every time point throughout the study, as well as a good tolerance and systemic safety profile compared to latanoprost.

용도Bimatoprost is a prostaglandin analog used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure (IOP) by increasing the outflow of aqueous fluid from the eyes. It ha

일반 설명Bimatoprost (Lumigan) is supplied as a sterile 0.03%ophthalmic solution in 2.5- and 5.0-mL sizes. The recommendeddosage of bimatoprost is limited to one drop intothe affected eye once daily in the evening. Increased usagemay decrease its beneficial effect. If used concurrently withother IOP-lowering drugs, a waiting period of 5 minutesshould separate administrations.

상·하류 제품 정보

하류 제품

(5E)-비마토프로스트